

**PANCREATIC β -CELL ELECTRICAL
ACTIVITY AND INSULIN SECRETION: OF
MICE AND MEN**

Patrik Rorsman^{1,2} and Frances M Ashcroft³




FIGURE 1. Expression analysis of hormones (A) and glucose transporters in mouse and human β -cells. Values here and in subsequent figures are means of published RNAseq data in mouse (3, 147) and human (69, 480) β -cells. RPKM indicates Reads Per Kilobase of transcript per Million mapped reads. Note that the β -cell fractions were obtained by fluorescence-activated cell sorting and were devoid of any mRNA for glucagon or somatostatin but contain low levels of *IAPP*. For clarity, only human gene names (i.e. in upper case italics) are given.

APPENDIX




Figure 2. *A*: Relative expression of Cl⁻ channels in mouse and human β-cells. Data are expressed relative to the sum of all genes displayed (i.e. RPKM/ΣRPKM). *B*: As in *A* but showing data for Trp channels.

APPENDIX




Figure 3. A-B: Relative expression of the pore-forming Ca^{2+} channel α -subunits (*CACNA1x*) (A) or auxiliary $\alpha_2\delta$ (*CACNA2D*), β - (*CACNBx*) and γ - (*CACNGx*) subunits (where x stands for a letter or number) (B).

APPENDIX




Figure 4. A-B: Relative expression of the pore-forming Na⁺ channel α-subunits (*SCNxA*) (A) and auxiliary β-subunits (*SCNxB*) (B). Note that the numbering of the proteins (Nav1.1-Nav1.9) and genes (*SCN1A-11A*) do not correspond.

APPENDIX




Figure 5. *A-B:* Relative expression of the pore-forming (*A*) or auxiliary subunits (*B*) of voltage-gated K⁺ channels in mouse and human β-cells.




Figure 6. Relative expression of small- (A) and large-conductance (B) Ca²⁺-activated K⁺ channels (*KCNNx* and *KCNMx*). Expression has been normalized to the aggregate expression of all *KCNNs* (ΣRPKM_{KCNN}).




Figure 7. *A:* Relative expression of inwardly rectifying K⁺ channels (*KCNJx*). Expression has been normalized to the aggregate expression of all *KCNJs* ($\Sigma\text{RPKM}_{\text{KCNJ}}$). *B:* Expression of SUR1 (*ABCC8*, likewise normalized to $\Sigma\text{RPKM}_{\text{KCNJ}}$). Note that the expression of *KCNJ11* and *ABCC8* is displayed using a different ordinate scale than the other *KCNJs*.




Figure 8. *A*: Relative expression of two-pore K⁺ channels (*KCNKx*). Expression has been normalized to the aggregate expression of all *KCNKs* (Σ RPKM). *B*: Comparison of *KCNK16* expression with *KCNJ11* (values in RPKM).

APPENDIX




Figure 9. Relative expression of the intracellular ion channels: ryanodine receptors ((*RYRx*), InsP₃ receptors (*ITPRx*) and two-pore channels (*TPCNx*).




Figure 10. Relative expression of *GJAs*, *GJBs*, *GJCs* and *GJDs*.

APPENDIX




Figure 11. *A:* Relative expression of cationic amino acid transporters (y+ system) in mouse and human β -cells. *SLC7A14* mediates uptake of cationic amino acids into lysosomes and may not be important for generation of electrical activity. Human and mouse β -cells express high levels of *SLC7A5* and *SLC7A8*, which is believed to transport neutral amino acids when associated with *SLC3A2*. *B:* As in *A*, but showing expression of neutral amino acid transporters. *C:* As in *A*, but displaying expression of Na^+ -dependent neutral amino acid transporters (SNATs). In addition to the high expression of *SLC38A2* and *A4*, both mouse and human β -cells also express the putative neutral amino acid transporter *SLC38A10*. *D:* Absolute expression (in RPKM) of *SLC1A4*, *SLC7A2*, *SLC7A5* and *Slc38A2* in mouse and human β -cells analyzed as described in legend to Figure 2D. *E:* Relative expression of free fatty acid receptors (*FFARs*) in mouse and human β -cells.

APPENDIX




Figure 12. *A*: Expression (in RPKM) of receptors for stimulatory and inhibitory agonists. Abbreviations: *CHRM*s, cholinergic receptors muscarinic; *CHRNA*s, cholinergic receptor nicotinic α -subunit; *FFAR*s, free fatty acid receptors; *ADR*s, adrenergic receptors; *GALR*s, galanin receptors; *INSR*, insulin receptor; *SSTR*s, somatostatin receptors. *B*: Relative expression of muscarinic receptors (*CHRM**x*). *C*: As in *B* but showing relative expression of nicotinic receptor α - (*CHRNA**x*), β - (*CHRNB**x*), δ - (*CHRND*), ϵ - (*CHRNE*) and γ - (*CHRNG**x*) subunits. Note that expression of *Chrn*s is very low in mouse β -cells so the functional significance of *Chrna4* is uncertain. *D*: As in *B* but showing relative expression of adrenergic α_1 - (*ADRA1**x*), α_2 - (*ADRA2**x*) and β -receptors (*ADRB**x*). *E*: Relative expression of somatostatin (*SSTR**x*), α_2 (*ADRA2A*), galanin (*GAL**x*), ghrelin (*GHSR*) and leptin (*LEPR*) receptors normalized to the aggregate expression of the SSTRs (Σ RPKM_{SSTR1-5}).




Figure 13. *A*: Relative expression of ionotropic ($P2RXx$) and metabotropic ($P2RYx$) purinergic receptors in mouse and human β -cells. *B*: Comparison of expression (in RPKM) of glycine receptor α - ($GLRAx$) and β -subunits ($GLRB$), ionotropic GABA_A α - ($GABRA1-6$) and β -subunits ($GABRB1-3$) and metabotropic GABA_B ($GABRBx$) receptors. Note that mouse β -cells are almost devoid of GABA_A receptors. *C*: As in *A*, but showing relative expression of glycine receptor α -subunits ($GLRAx$) normalized to the aggregate expression of $GLRAs$.

Glutamatergic




Figure 14. *A*: Comparison of expression (in RPKM) of AMPA (*GRIA1-4*), kainate (*GRIKx*) and NMDA (*GRINx*)-subunits. *B*: Relative expression of *GRIAx*, *GRIKx* and *GRINx* normalized to aggregate expression of all ionotropic glutamate receptors. *C*: As in *B* but comparing expression of metabotropic glutamate receptors (*GRMx*) in mouse and human β -cells. Note very low expression of *GRIMs* in mouse β -cells. *D*: As in *B* but showing relative expression of *GRMx* in human β -cells (relative expression in mouse β -cells not shown because of low expression).




Figure 15. *A:* Relative expression of Rab3 (*RAB3x*) in mouse and human β -cells. *B:* As in *A* but showing Rab27 (*RAB27x*). *C:* As in *A* but showing RIM (*RIMx*). *D:* As in *A* but showing RAPGEFs (*RAPGEFx*). *E:* Comparison of expression (in RPKM) of *RAPGEF4* in mouse and human β -cells. Note that expression in mouse β -cells is much higher than in human β -cells. *F:* As in *A* but showing relative expression of *RPH3A* and *RPH3AL*.




Figure 16. *A*: Relative expression of syntaxins (STXs) in mouse and human β -cells. *B*: Expression (in RPKM) of *STX1A* in mouse and human β -cells. Note the much higher expression in human than in mouse β -cells.

APPENDIX




Figure 17. *A*: Relative expression of SNAP23 and 25 (*SNAPx*) in mouse and human β -cells. *B*: As in *A* but showing VAMPs (*VAMPx*). *C*: As in *A* but showing syntaxin-binding proteins (*STXBPx*). *D*: As in *A* but showing Munc13 (*UNC13x*). *E*: As in *A* but showing complexes (*CPLXx*). *F*: As in *A* but showing synaptotagmin-like proteins (*SYTLx*). *G*: Comparison of expression (in RPKM) of *SYTL4* in mouse (black) and human β -cells (red). Note absence of *SYTL4* in human β -cells.




Figure 18. Relative expression of Ca^{2+} -dependent (A) and -independent (B) synaptotagmins in mouse and human β -cells. Expression has been normalized to the summed expression of the Ca^{2+} -dependent synaptotagmins (*SYT1*, *SYT2*, *SYT3*, *SYT5*, *SYT6*, *SYT7*, *SYT9*, *SYT10*). For display, the expression of the Ca^{2+} -dependent and -independent SYTs (*right*) has been separated. Note the high expression of Ca^{2+} -independent SYTs.